Herantis Pharma Oyj

Helsinki Stock Exchange HRTIS.HE

Herantis Pharma Oyj Gross Profit Margin for the year ending December 31, 2023

Herantis Pharma Oyj Gross Profit Margin is NA for the year ending December 31, 2023. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Helsinki Stock Exchange: HRTIS.HE

Herantis Pharma Oyj

CEO	Dr. Antti Vuolanto D.Sc. (Tech)
IPO Date	June 11, 2014
Location	Finland
Headquarters	Bertel Jungin Aukio 1
Employees	11
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.

Key trends

Past 5 years